Non Small Cell Lung Cancer Clinical Trial
Official title:
Pre-Operative Assessment of Chest Wall Invasion in Non-Small Cell Lung Cancer (NSCLC)Using Pre-Operative, Surgeon Performed Ultrasound
Non-Small Cell Lung Cancer (75% of lung cancer) is associated with involvement of the
parietal pleura and or chest wall (soft tissue and/or bone) in 5-8% of patients. Invasion of
the chest wall increases the T staging in the Tumor, Node, Mestasis (TNM) classification
system of lung cancer to a T3 and is associated with decreased survival and more extensive
operative procedures. The reported 5-year survival for patients with T2 tumors is 58%
compared to 38% in patients with T3 lesions. The American college of Chest Physician has
still not identified the best tool to assess chest wall invasion by lung cancer, CT-Scan
being used by physicians for this assessment. In some studies, CT scan has been shown to
have a sensitivity ranging from 42 % to 68 % in assessing chest wall invasion, and a
specificity ranging from 66 % to 100 %.
Trans-thoracic Ultrasound (US) has the capacity of allowing for dynamic real-time imaging of
the pulmonary lesion and the chest wall. Therefore, US has the potential to allow for the
appreciation of subtle findings related to the movement of the lesion and lung over the
chest wall. Hence, US might be an accurate tool to assess chest wall invasion by lung
cancer; thus improving pre-operative diagnosis, staging and operative planning of patient
with chest wall invasion.
However US is not currently utilized in the pre-operative assessment of patients with lung
cancer invading the pleura and chest wall, and has not been extensively studied.
In some rare studies evaluating the accuracy of US, results have shown a sensitivity ranging
from 89% to 100% and a specificity ranging from 95% to 98% for US detecting chest wall
invasion by lung cancer. However those studies got criticized. Bandi et al study, got
criticized by the fact that the operators in the study were experienced interventional
pulmonologists who perform hundreds of thoracic and endoscopic ultrasound per year. Nobuo et
al study took place in 1993, since when the device of US has evolved, the investigators can
not apply with certainty the findings of this study.
Consequently, there is a need to conduct a study to evaluate the accuracy of US to assess
chest wall invasion by lung cancer.
In this prospective study the investigators will assess the accuracy of US, and then compare
it to the accuracy of the CT-Scan
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |